Recombinant protein · Protein replacement: Plasma kallikrein (KLKB1), Complement component 1s (C1s) (C1S) and Coagulation factor XIIa (F12) · developed by Pharming Healthcare
Conestat alfa is a recombinant form of human C1 esterase inhibitor, a serine protease inhibitor. It irreversibly binds and inhibits several proteases of the contact and complement systems, including activated C1s, kallikrein, factor XIIa and factor XIa, reducing bradykinin production and vascular permeability. It is used in hereditary angioedema and is studied in coronavirus infections, acute ischemic stroke and acute renal injury.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 30, 2020). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05145283 | Phase 2 | Acute Ischemic Stroke | Completed | PHAR |
| NCT04414631 | Phase 2 | Coronavirus Infections | Terminated | PHAR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Ischemic StrokeAcute Renal InjuryCoronavirus Infections
Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.
See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PHAR catalysts and pipeline →